Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
James Januzzi, MD
PeerMartin Maron, MD
PeerMarianna Fontana, MD
PeerLong-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Alexander Fanaroff, MD
PeerHadley Wilson, MD
PeerAngiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Akshay S. Desai, MD
PeerACC 2024: The PIONEER AF-PCI Trial
Manesh R. Patel, MD
PeerManesh R. Patel, MD
PeerACC 2024: VOYAGER PAD Part 1
Marc P. Bonaca, MD, MPH
PeerACC 2024: VOYAGER PAD Part 2
Marc P. Bonaca, MD, MPH
PeerDeep Learner: Building AI to Improve Cardiovascular Care
Pierre Elias, MD
PeerAgainst the Odds: Improving Survival for Children with Pulmonary Vein Stenosis
Christopher Petit, MD
PeerConfronting the Complexities of Reaching LDL-C Thresholds in Patients with Primary Hyperlipidemia
Michael Bloch, MD
PeerConversations With Cardiologists: Clinical Perspectives on the Treatment of HFmrEF and HFpEF
Primary Hyperlipidemia: Fresh look at an LDL-C Therapy and its Long-Term Data
Overcoming Real World Challenges of LDL-C Management: Looking Beyond Statin Therapy